LeMaitre Vascular Inc Cash Flow Conversion Efficiency
LeMaitre Vascular Inc cash flow conversion efficiency. Based on the latest financial reports, LeMaitre Vascular Inc (LMAT) has a cash flow conversion efficiency ratio of 0.037x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($15.09 Million) by net assets ($406.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of LeMaitre Vascular Inc (2004–2025)
Cash flow conversion efficiency of LeMaitre Vascular Inc from 2004 to 2025. This chart illustrates how LeMaitre Vascular Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View LeMaitre Vascular Inc (LMAT) share price today for real-time trading data and today's change.
LeMaitre Vascular Inc Cash Flow Conversion Ratio Explained
LeMaitre Vascular Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
LeMaitre Vascular Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LeMaitre Vascular Inc ranked by their cash flow conversion efficiency. Also see market value of LeMaitre Vascular Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
UIE PLC
CO:UIE
|
0.044x |
|
Sparebank 1 Nord-Norge
OL:NONG
|
0.132x |
|
Optowide Technologies Co. Ltd. A
SHG:688195
|
N/A |
|
TKH Group NV
AS:TWEKA
|
0.168x |
|
Jiangnan Mould & Plastic Technology Co Ltd
SHE:000700
|
0.088x |
|
Gelsenwasser AG
F:WWG
|
0.031x |
|
Veris Residential Inc
NYSE:VRE
|
0.011x |
|
Stolt-Nielsen Limited
OL:SNI
|
0.039x |
Annual Cash Flow Conversion Efficiency for LeMaitre Vascular Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of LeMaitre Vascular Inc from 2004 to 2025. Review LMAT free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $393.52 Million | $81.25 Million | 0.206x | +57.83% |
| 2024-12-31 | $337.29 Million | $44.12 Million | 0.131x | +6.04% |
| 2023-12-31 | $297.90 Million | $36.75 Million | 0.123x | +30.38% |
| 2022-12-31 | $268.20 Million | $25.38 Million | 0.095x | -31.49% |
| 2021-12-31 | $254.15 Million | $35.10 Million | 0.138x | -31.51% |
| 2020-12-31 | $172.57 Million | $34.80 Million | 0.202x | +110.69% |
| 2019-12-31 | $148.14 Million | $14.18 Million | 0.096x | -36.10% |
| 2018-12-31 | $130.24 Million | $19.51 Million | 0.150x | -28.11% |
| 2017-12-31 | $109.77 Million | $22.87 Million | 0.208x | +7.89% |
| 2016-12-31 | $87.50 Million | $16.90 Million | 0.193x | +31.48% |
| 2015-12-31 | $77.88 Million | $11.44 Million | 0.147x | +81.73% |
| 2014-12-31 | $68.21 Million | $5.51 Million | 0.081x | -15.16% |
| 2013-12-31 | $56.56 Million | $5.39 Million | 0.095x | +6.69% |
| 2012-12-31 | $52.89 Million | $4.72 Million | 0.089x | +46.71% |
| 2011-12-31 | $52.09 Million | $3.17 Million | 0.061x | -54.82% |
| 2010-12-31 | $52.36 Million | $7.05 Million | 0.135x | +19.37% |
| 2009-12-31 | $48.21 Million | $5.44 Million | 0.113x | +788.45% |
| 2008-12-31 | $45.75 Million | $581.00K | 0.013x | +133.79% |
| 2007-12-31 | $48.59 Million | $-1.83 Million | -0.038x | -262.25% |
| 2006-12-31 | $50.70 Million | $-526.00K | -0.010x | +84.00% |
| 2005-12-31 | $18.54 Million | $-1.20 Million | -0.065x | -157.11% |
| 2004-12-31 | $14.81 Million | $1.68 Million | 0.114x | -- |
About LeMaitre Vascular Inc
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arte… Read more